Polyrizon (PLRZ) Competitors

$13.98 +0.27 (+1.97%)

Closing price 04:00 PM Eastern

Extended Trading

$13.90 -0.08 (-0.57%)

As of 07:38 PM Eastern

PLRZ vs. KLRS, CGTX, BMEA, COYA, and ENGN

Should you buy Polyrizon stock or one of its competitors? MarketBeat compares Polyrizon with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Polyrizon include Kalaris Therapeutics (KLRS), Cognition Therapeutics (CGTX), Biomea Fusion (BMEA), Coya Therapeutics (COYA), and enGene (ENGN). These companies are all part of the "pharmaceutical products" industry.

How does Polyrizon compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

66.1% of Kalaris Therapeutics shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kalaris Therapeutics presently has a consensus target price of $15.60, indicating a potential upside of 231.84%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kalaris Therapeutics is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Kalaris Therapeutics has a beta of 0.15, suggesting that its stock price is 85% less volatile than the broader market. Comparatively, Polyrizon has a beta of -2.04, suggesting that its stock price is 304% less volatile than the broader market.

Polyrizon's return on equity of 0.00% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Polyrizon	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

In the previous week, Kalaris Therapeutics had 2 more articles in the media than Polyrizon. MarketBeat recorded 6 mentions for Kalaris Therapeutics and 4 mentions for Polyrizon. Polyrizon's average media sentiment score of 1.03 beat Kalaris Therapeutics' score of 0.38 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Polyrizon	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kalaris Therapeutics beats Polyrizon on 8 of the 12 factors compared between the two stocks.

How does Polyrizon compare to Cognition Therapeutics?

Polyrizon (NASDAQ:PLRZ) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

Polyrizon has a beta of -2.04, suggesting that its share price is 304% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market.

43.4% of Cognition Therapeutics shares are held by institutional investors. 14.4% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Polyrizon's return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Cognition Therapeutics	N/A	-72.68%	-53.07%

Cognition Therapeutics has a consensus target price of $3.33, suggesting a potential upside of 200.30%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cognition Therapeutics is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Cognition Therapeutics had 1 more articles in the media than Polyrizon. MarketBeat recorded 5 mentions for Cognition Therapeutics and 4 mentions for Polyrizon. Polyrizon's average media sentiment score of 1.03 beat Cognition Therapeutics' score of 0.50 indicating that Polyrizon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polyrizon	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cognition Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cognition Therapeutics beats Polyrizon on 7 of the 11 factors compared between the two stocks.

How does Polyrizon compare to Biomea Fusion?

Biomea Fusion (NASDAQ:BMEA) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Polyrizon's return on equity of 0.00% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Polyrizon	N/A	N/A	N/A

In the previous week, Biomea Fusion had 2 more articles in the media than Polyrizon. MarketBeat recorded 6 mentions for Biomea Fusion and 4 mentions for Polyrizon. Polyrizon's average media sentiment score of 1.03 beat Biomea Fusion's score of -0.86 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Overall Sentiment
Biomea Fusion	Negative
Polyrizon	Positive

Biomea Fusion has a beta of -0.32, suggesting that its share price is 132% less volatile than the broader market. Comparatively, Polyrizon has a beta of -2.04, suggesting that its share price is 304% less volatile than the broader market.

Biomea Fusion presently has a consensus price target of $8.29, suggesting a potential upside of 579.16%. Given Biomea Fusion's stronger consensus rating and higher possible upside, equities analysts plainly believe Biomea Fusion is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

96.7% of Biomea Fusion shares are owned by institutional investors. 18.4% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Summary

Biomea Fusion beats Polyrizon on 8 of the 12 factors compared between the two stocks.

How does Polyrizon compare to Coya Therapeutics?

Polyrizon (NASDAQ:PLRZ) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Coya Therapeutics has a consensus target price of $16.00, indicating a potential upside of 250.11%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Coya Therapeutics is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Coya Therapeutics had 3 more articles in the media than Polyrizon. MarketBeat recorded 7 mentions for Coya Therapeutics and 4 mentions for Polyrizon. Polyrizon's average media sentiment score of 1.03 beat Coya Therapeutics' score of 0.45 indicating that Polyrizon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polyrizon	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coya Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

39.8% of Coya Therapeutics shares are owned by institutional investors. 12.0% of Coya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Polyrizon has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Polyrizon's return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Coya Therapeutics	-266.10%	-55.86%	-48.86%

Polyrizon has higher earnings, but lower revenue than Coya Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Coya Therapeutics	$7.95M	13.49	-$21.23M	-$1.15	N/A

Polyrizon has a beta of -2.04, meaning that its share price is 304% less volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

Summary

Coya Therapeutics beats Polyrizon on 8 of the 13 factors compared between the two stocks.

How does Polyrizon compare to enGene?

enGene (NASDAQ:ENGN) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

64.2% of enGene shares are owned by institutional investors. 10.5% of enGene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, enGene had 6 more articles in the media than Polyrizon. MarketBeat recorded 10 mentions for enGene and 4 mentions for Polyrizon. Polyrizon's average media sentiment score of 1.03 beat enGene's score of -0.04 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Polyrizon	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

enGene currently has a consensus target price of $12.68, indicating a potential upside of 728.88%. Given enGene's stronger consensus rating and higher possible upside, research analysts plainly believe enGene is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Polyrizon's return on equity of 0.00% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-55.83%	-45.74%
Polyrizon	N/A	N/A	N/A

enGene has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market. Comparatively, Polyrizon has a beta of -2.04, suggesting that its share price is 304% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.25	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Summary

enGene beats Polyrizon on 7 of the 11 factors compared between the two stocks.

Get Polyrizon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLRZ vs. The Competition

Export

Metric	Polyrizon	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$25.66M	$3.25B	$6.25B	$12.23B
Dividend Yield	N/A	2.34%	2.80%	5.32%
P/E Ratio	N/A	18.52	20.79	25.05
Price / Sales	N/A	270.32	531.21	72.69
Price / Cash	N/A	124.58	43.09	54.25
Price / Book	1.07	6.60	9.81	6.83
Net Income	-$3.34M	$24.18M	$3.55B	$335.69M
7 Day Performance	-6.86%	-3.56%	-2.07%	-2.03%
1 Month Performance	22.52%	-7.86%	-3.90%	-1.90%
1 Year Performance	41.21%	51.80%	29.39%	27.36%

Polyrizon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLRZ Polyrizon	1.1001 of 5 stars	$13.98 +2.0%	N/A	+38.5%	$25.66M	N/A	N/A	N/A	Positive News Short Interest Decrease
KLRS Kalaris Therapeutics	3.544 of 5 stars	$5.22 +8.1%	$15.60 +198.9%	N/A	$111.05M	N/A	N/A	110	Earnings Report Gap Down
CGTX Cognition Therapeutics	3.5246 of 5 stars	$1.20 flat	$3.33 +177.8%	+235.2%	$107.40M	N/A	N/A	20
BMEA Biomea Fusion	2.1223 of 5 stars	$1.43 -3.4%	$8.29 +479.4%	-17.8%	$107.00M	N/A	N/A	50
COYA Coya Therapeutics	2.7706 of 5 stars	$5.26 +15.9%	$16.00 +204.2%	-17.0%	$106.50M	$7.95M	N/A	6	News Coverage Earnings Report Analyst Downgrade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLRZ) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Polyrizon (PLRZ) Competitors

PLRZ vs. KLRS, CGTX, BMEA, COYA, and ENGN

How does Polyrizon compare to Kalaris Therapeutics?

Summary

How does Polyrizon compare to Cognition Therapeutics?

Summary

How does Polyrizon compare to Biomea Fusion?

Summary

How does Polyrizon compare to Coya Therapeutics?

Summary

How does Polyrizon compare to enGene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ vs. The Competition

Polyrizon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Polyrizon (PLRZ) Competitors

PLRZ vs. KLRS, CGTX, BMEA, COYA, and ENGN

How does Polyrizon compare to Kalaris Therapeutics?

Do institutionals and insiders have more ownership in KLRS or PLRZ?

Do analysts recommend KLRS or PLRZ?

Which has more volatility and risk, KLRS or PLRZ?

Is KLRS or PLRZ more profitable?

Which has preferable valuation & earnings, KLRS or PLRZ?

Does the media prefer KLRS or PLRZ?

Summary

How does Polyrizon compare to Cognition Therapeutics?

Which has better earnings & valuation, PLRZ or CGTX?

Which has more risk and volatility, PLRZ or CGTX?

Do institutionals & insiders have more ownership in PLRZ or CGTX?

Is PLRZ or CGTX more profitable?

Do analysts rate PLRZ or CGTX?

Does the media refer more to PLRZ or CGTX?

Summary

How does Polyrizon compare to Biomea Fusion?

Is BMEA or PLRZ more profitable?

Does the media refer more to BMEA or PLRZ?

Which has more volatility & risk, BMEA or PLRZ?

Do analysts prefer BMEA or PLRZ?

Do insiders & institutionals have more ownership in BMEA or PLRZ?

Which has stronger earnings & valuation, BMEA or PLRZ?

Summary

How does Polyrizon compare to Coya Therapeutics?

Do analysts rate PLRZ or COYA?

Does the media favor PLRZ or COYA?

Do institutionals & insiders believe in PLRZ or COYA?

Is PLRZ or COYA more profitable?

Which has better valuation and earnings, PLRZ or COYA?

Which has more risk & volatility, PLRZ or COYA?

Summary

How does Polyrizon compare to enGene?

Do insiders and institutionals believe in ENGN or PLRZ?

Does the media refer more to ENGN or PLRZ?

Do analysts rate ENGN or PLRZ?

Is ENGN or PLRZ more profitable?

Which has more volatility and risk, ENGN or PLRZ?

Which has preferable valuation & earnings, ENGN or PLRZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ vs. The Competition

Polyrizon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools